RxDoctor Payments Data

Allan Jaffe, MD

Cardiovascular Disease · Rochester, MNNPI 1538146626

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 35.3% of the total. Reporting peaked in 2020 at $33,271 and has fallen 82.5% since, to $5,829 in 2025. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$110,605in general payments, 2019–2025

Across 84 payments — averaging $1316.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$39K
  • Roche Diagnostics International Ltd$28K
  • Abbott$14K
  • Amgen$12K
  • Roche Diagnostics Corporation$8K
  • Radiometer America, Inc$4K
  • plus $6K from 6 others
$9,593in research payments, 2019–2025

Across 1 payment — averaging $9593.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$10K

What the payments were for

  • Consulting fees$59,43354%
  • Speaking & faculty fees$19,55018%
  • Travel & lodging$28,74426%
  • Food & beverage$2,8773%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,605 in reported general payments places this provider in the 90th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024
$206,751
Medicare patients
10,056
Services billed
14,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Rochester

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →